Details of Disease

General Information of Disease (ID: DIS7PYN3)

Disease Name Basal cell carcinoma
Synonyms basal cell cancer; epithelioma, basal cell; malignant basal cell neoplasm
Disease Class 2C32: Basal cell carcinoma
Definition A carcinoma involving the basal cells.
Disease Hierarchy
DIS37IXW: Basal cell neoplasm
DISH9F1N: Carcinoma
DIS7PYN3: Basal cell carcinoma
ICD Code
ICD-11
ICD-11: 2C32
ICD-10
ICD-10: C44
Expand ICD-11
'XH9SA7
Disease Identifiers
MONDO ID
MONDO_0020804
UMLS CUI
C0007117
MedGen ID
2870
SNOMED CT ID
1338007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Vismodegib DM5IXKQ Approved Small molecular drug [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Rostaporfin DM7SAKN Phase 3 Small molecular drug [2]
LDE225 DMM9F25 Phase 2 Small molecular drug [3]
Patidegib DM2NJYC Phase 2 NA [2]
Remetinostat DMJIB89 Phase 2 NA [2]
STP705 DMO7RO5 Phase 2 NA [4]
AIV001 DML0GIU Phase 1/2 Small molecular drug [5]
C31510 DMUKK9B Phase 1 NA [6]
CIGB-128 DMB2MKU Phase 1 NA [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 14 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CTSH TT3G406 Limited Genetic Variation [8]
CTSS TTUMQVO Limited Genetic Variation [8]
CYP1B1 TTI84H7 Limited Genetic Variation [8]
FOXP1 TT0MUCI Limited Genetic Variation [8]
GPR183 TTME5YJ Limited Genetic Variation [8]
HAL TTXQOZW Limited Genetic Variation [8]
PPARGC1B TTKSQ3W Limited Genetic Variation [8]
RAC1 TT2M9CG Limited Genetic Variation [8]
SLC6A17 TTIMLZ6 Limited Genetic Variation [8]
SMC2 TTS8D17 Limited Genetic Variation [8]
MC1R TT0MV2T Strong Genetic Variation [8]
SMO TT8J1S3 Strong Genetic Variation [9]
TYR TTULVH8 Strong Genetic Variation [8]
XPA TTGT87E Strong Genetic Variation [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC45A2 DTNCJAT Limited Genetic Variation [8]
------------------------------------------------------------------------------------
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
TGM3 DEOEB3Q Limited Genetic Variation [8]
------------------------------------------------------------------------------------
This Disease Is Related to 33 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ATP11A OT7M9ZDK Limited Genetic Variation [8]
BACH2 OT17GS18 Limited Genetic Variation [8]
CCDC88B OTEDUI2J Limited Genetic Variation [8]
CLPTM1L OTDJWQXI Limited Genetic Variation [8]
COLEC10 OTMBADGZ Limited Genetic Variation [8]
CPVL OTOJL31C Limited Genetic Variation [8]
EFEMP2 OT0I2B4J Limited Genetic Variation [8]
EXO1 OTI87RS5 Limited Genetic Variation [8]
FLACC1 OTZN9TZV Limited Genetic Variation [8]
FRMD4A OTJDTIK2 Limited Genetic Variation [8]
GPX4 OTRAFFX2 Limited Genetic Variation [8]
HAUS6 OT7ZVR57 Limited Genetic Variation [8]
HERC2 OTNQYKOB Limited Genetic Variation [8]
IRF4 OT1DHQ1P Limited Genetic Variation [8]
JDP2 OTW35WKX Limited Genetic Variation [8]
KANK1 OT2E7A6W Limited Genetic Variation [8]
KRT5 OTVGI9HT Limited Genetic Variation [8]
LPP OT6TU8SE Limited Genetic Variation [8]
PADI6 OTS42I3K Limited Genetic Variation [11]
PTPN22 OTDCNTC3 Limited Genetic Variation [8]
RALY OT78NNWY Limited Genetic Variation [8]
RCC2 OTUJVTLS Limited Genetic Variation [8]
RGS22 OTCTFGW6 Limited Genetic Variation [8]
SCAF1 OT16TM3N Limited Genetic Variation [8]
STN1 OT8UWRA3 Limited Genetic Variation [8]
TNS3 OTPG2D8Z Limited Genetic Variation [8]
TRPS1 OT7XPPEL Limited Genetic Variation [8]
ERCC2 OT1C8HQ4 Strong Genetic Variation [12]
KRT15 OTS6WLF7 Strong Altered Expression [13]
LGALS7 OTMSVI7R Strong Biomarker [14]
NDUFA1 OTKBUQXP Strong Altered Expression [15]
PLAGL1 OTZAO900 Strong Altered Expression [16]
PTCH1 OTMG07H5 Strong Genetic Variation [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DOT(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5.
4 ClinicalTrials.gov (NCT04669808) Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04470726) Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma. U.S. National Institutes of Health.
6 ClinicalTrials.gov (NCT01251562) Safety Study of Sterile Compound c31510 for Injection to Subjects With Solid Tumors. U.S. National Institutes of Health.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037683)
8 Combined analysis of keratinocyte cancers identifies novel genome-wide loci.Hum Mol Genet. 2019 Sep 15;28(18):3148-3160. doi: 10.1093/hmg/ddz121.
9 PTCH1 and SMO gene alterations in keratocystic odontogenic tumors.J Dent Res. 2008 Jun;87(6):575-9. doi: 10.1177/154405910808700616.
10 Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect. 2007 Aug;115(8):1231-6. doi: 10.1289/ehp.10096.
11 New basal cell carcinoma susceptibility loci.Nat Commun. 2015 Apr 9;6:6825. doi: 10.1038/ncomms7825.
12 Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma.Hum Mutat. 2005 Apr;25(4):353-9. doi: 10.1002/humu.20158.
13 Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.J Dermatol. 2008 Aug;35(8):499-502. doi: 10.1111/j.1346-8138.2008.00510.x.
14 Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?.Histol Histopathol. 2009 Jan;24(1):41-8. doi: 10.14670/HH-24.41.
15 Downregulation of NDUFA1 and other oxidative phosphorylation-related genes is a consistent feature of basal cell carcinoma.Exp Dermatol. 2005 May;14(5):336-48. doi: 10.1111/j.0906-6705.2005.00278.x.
16 The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.Mol Cancer Res. 2005 Sep;3(9):483-92. doi: 10.1158/1541-7786.MCR-05-0019.